ViewRay Inc. (VRAYQ)
Market Cap | 18.34K |
Revenue (ttm) | 105.86M |
Net Income (ttm) | -110.42M |
Shares Out | n/a |
EPS (ttm) | -0.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 184 |
Open | 0.0001 |
Previous Close | n/a |
Day's Range | 0.0001 - 0.0001 |
52-Week Range | n/a |
Beta | 0.77 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About VRAYQ
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network ... [Read more]
Financial Performance
In 2022, ViewRay's revenue was $102.21 million, an increase of 45.76% compared to the previous year's $70.12 million. Losses were -$107.33 million, -2.47% less than in 2021.
Financial StatementsNews
Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers—Let's Preserve ViewRay Technology
WASHINGTON--(BUSINESS WIRE)--In light of ViewRay Systems recent announcement that it would close its doors on October 25, 2023, Dr. Suthanthiran, President/Founder of TeamBest Global Companies (TBG) a...
Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
WASHINGTON--(BUSINESS WIRE)--Since the announcement regarding the closing of ViewRay on October 25, 2023, competitors have raced to decommission the ViewRay Systems, replacing them with their own prod...
Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
WASHINGTON--(BUSINESS WIRE)--Krishnan Suthanthiran offers a solution for continued support and service to ViewRay customers.
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets
DENVER , July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (Nasdaq: VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock...
ViewRay® Files Voluntary Chapter 11 Petitions
Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER , July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that it and certain of i...
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System
First cancer center in Oklahoma and fourth VA medical center to offer advanced MRI-guided radiation therapy to treat cancer. DENVER , June 13, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announc...
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting
50 clinical presentations and posters highlight benefits of MRI-guided radiation adaptive therapy DENVER , May 12, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's ...
ViewRay Announces First Quarter 2023 Results
DENVER , May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total rev...
ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023
DENVER , May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss...
ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value
DENVER , April 13, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today provided a business update and announced preliminary financial results for the quarter ended March 31, 2023. ...
ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023
DENVER , April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers ...
GenesisCare Launches ViewRay MRIdian® MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center, Empowering Cancer Patient Care with an Innovative Radiotherapy Approach with Reduced Side Effects, Fewer Sessions Needed
FORT MYERS, Fla.--(BUSINESS WIRE)--GenesisCare, one of the leading integrated cancer care providers in the United States, Australia, Spain, and the United Kingdom, will launch ViewRay's advanced MRIdi...
Military University Hospital Prague Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Treat Cancer Patients
First and only MRIdian in the Czech Republic to bring advanced MRI-guided radiation therapy to the region DENVER , March 7, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the Czech ...
Siteman Cancer Center at Washington University Treats 2,000th Patient with MRIdian® MRI-Guided Radiation Therapy
World's first MRIdian center at Barnes-Jewish Hospital continues to lead the way for advanced precision cancer therapy with MRI-guided radiation DENVER , March 2, 2023 /PRNewswire/ -- ViewRay, Inc. (N...
ViewRay Announces Fourth Quarter and Full Year 2022 Results
DENVER , Feb. 27, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022. Full Year 202...
ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023
DENVER , Jan. 31, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of fourth quarter 2022 financial results. ViewRay will hold a conference call to dis...
ViewRay Enters into Cooperation Agreement with Hudson Executive Capital
CLEVELAND , Jan. 20, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Sai Nanduri, Senior Investme...
Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
MIRAGE phase III randomized controlled trial shows a significant reduction in GU and GI toxicities with MRIdian® MRI-guided versus CT-guided SBRT DENVER , Jan. 12, 2023 /PRNewswire/ -- ViewRay, Inc. (...
ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer
DENVER , Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. Th...
Chindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer Treatment
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China DENVER , Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chinde...
University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems
Immediate order of one system with ability to purchase an additional three systems DENVER , Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospitals (UH)...
ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility
Facility includes senior secured term loan of up to $100 million and a revolving line of credit of up to $25 million DENVER , Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company")...
ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference
DENVER , Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the 34th Annual Piper Sandler Healthcare Conference. Scott Drake, President and Chi...
ViewRay® to Present at the Stifel 2022 Healthcare Conference
DENVER , Nov. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Stifel 2022 Healthcare Conference. Scott Drake, President and Chief Executive O...